CClinicalTrials.gg
Active, not recruitingNCT05373537Updated Apr 8, 2026

Treatment to Improve Sleep in Caregivers With Insomnia and a Child With Autism

An interventional study of Cognitive behavioral therapy for Insomnia in Autism Spectrum Disorder, Insomnia Chronic and Caregiver Burden, sponsored by University of Pennsylvania. Active, not recruiting at 2 sites in United States. Open to participants aged 3 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
3 Years to 100 Years
Sex
All
01

Study summary

Autism Spectrum Disorder (ASD) represents one of the most perplexing neurobiological disorders with a prevalence of 1 in 54 children. The lifelong challenging and disruptive behaviors often associated with ASD requires caregivers to change their behavior and modify their environments to provide an ecosystem for optimal outcomes for their child, family and themselves. ASD behaviors can have significant impact on caregivers mental health and family functioning, including the ability to develop and maintain healthy sleep routines. The caregiving population in US has a high prevalence of insomnia; two thirds of caregivers experiencing difficulties falling and/or staying asleep. The prevalence of insomnia in children with ASD is equally high, 60-80% experiencing night waking contributing to poor daytime behavior and disrupted sleep in the caregivers. This pilot RCT will focus on improving caregivers sleep in the context of caring for a child with ASD and insomnia with a multi-disciplinary team. The investigators will compare a home-based tailored CBT for Insomnia (CBT-I) versus a web-based Way to Health CBT-I intervention. This data will support a larger RCT with the Department of Defense funding opportunity through the Congressionally Directed Medical Research Program. This Autism Research Program focuses on improving lives of those living with ASD.

Read the detailed description

Overall objectives

The investigators propose to compare a home-based tailored CBT-I intervention versus a web-based Way to Health (WTH) platform tailored CBT-I intervention for caregivers with insomnia in the context of caring for a child with ASD and insomnia. This pilot RCT will further the investigators previous work and investigate the feasibility, acceptability, and efficacy of a web based versus home-based CBT-I intervention for both the caregiver with insomnia and the child with ASD and insomnia. The investigators also hope to gain a greater understanding of the relationships between child and caregiver sleep, caregiver psychiatric conditions, child behavior, and maternal self-efficacy. These findings will provide preliminary data for a larger RCT to improve sleep for all family members. The specific aims of this pilot study are:

  1. To determine the acceptability and feasibility of a RCT design utilizing a novel, web-based WTH platform versus a home- based CBT-I intervention to improve sleep of a caregiver with insomnia and a child with ASD and insomnia. The investigators plan to evaluate the recruitment, retention, randomization, and training required for this study.
  2. To examine the relationship between caregiver self- efficacy, caregiver psychiatric conditions and sleep, and child daytime behaviors and sleep pre and post intervention.
  3. To compare the effect of a home- based tailored CBT-I versus web based WTH CBT-I on child and caregiver sleep with a primary endpoint of total sleep time and sleep latency measured with Actigraphy, caregiver mental health scores, and child daytime behaviors.

Primary outcome variable(s)

  1. To determine the acceptability and feasibility of a RCT design with the Opinion Survey assessing acceptability with an 8 items rated on a 7- point Likert scale survey This study will be considered feasible if we obtain a 70% completion rate for the repeated measures. Acceptability of the web-based and home based will be determined by parent acceptability survey. This protocol will be considered acceptable to parents if the acceptability score is 70% or greater.
  2. To compare the effect of a home- based tailored CBT-I versus web based WTH CBT-I on child and caregiver sleep with a primary endpoint of total sleep time and sleep latency measured with Actigraphy Secondary outcome variable(s) To examine the relationship between caregiver self- efficacy, caregiver psychiatric conditions, child daytime behaviors and sleep parameters pre and post intervention. To examine the mediation effect of caregiver self-efficacy on the relationship between depressive symptoms, caregiver and child sleep, and child symptom severity and behavior, the investigators will use the Baron and Kenny 4-step regression model.71 Independent predictors of depressive symptoms will be tested and adjusted in all analytical steps. Mediation analysis will be performed for all subjects in a pooled sample, followed by a sensitivity analysis to determine the moderating role of child's symptom severity. Conduct a Sobel test to analyze the statistical significance of the mediation effect.

Background Autism Spectrum Disorder (ASD) represents one of the most perplexing neurobiological disorders with a prevalence of 1 in 54 children (1). Substantial heterogeneity exists in the degree of impairment, the collection of behavioral symptoms and the medical conditions associated with ASD. The lifelong challenging and disruptive behaviors often associated with ASD require caregivers to change their behavior and modify their environments to provide an ecosystem for optimal outcomes for their child, family and themselves. However, ASD behaviors can have a significant impact on caregivers mental health and family functioning, including the ability to develop and maintain healthy sleep routines (2). The caregiving population in the U.S. has a high prevalence of insomnia, with two thirds of caregivers experiencing difficulties falling and/or staying asleep. The prevalence of insomnia in children with ASD is equally high, with 60-80% experiencing night waking, contributing to poor daytime child behavior and disrupted caregiver sleep (3, 4). This pilot RCT will focus on improving caregivers sleep in the context of caring for a child with ASD and insomnia with a multi-disciplinary team approach. This pilot data will support a larger RCT with the Department of Defense (DoD) funding opportunity through the Congressionally Directed Medical Research Program. This Autism Research Program focuses on improving lives of those living with ASD.

The investigators recently completed study reveals that 36.6 % of mothers of children with ASD report a psychiatric disorder before and during pregnancy (5). Moreover, 30% of mothers of children with ASD report depression (6-13), revealing the significant vulnerability of this caregiving population. Evidence suggests that insomnia can be a precursor to onset or worsening of psychiatric conditions (14). Maternal depression is associated with lower family functioning, which affects physical, behavioral, and emotional outcomes of children (15-18). Notably, mothers depressive symptoms can interfere with and even blunt the effects of home-based interventions for children with ASD (8). This results in a cycle of poor child outcomes and greater need for intervention (19, 20). Our study of mothers of children with ASD demonstrated that maternal depression and self-efficacy impact child behaviors (21). Therefore, the investigators hypothesize that helping caregivers improve their sleep and their childs sleep, will have a positive impact on mood, cognition, and maternal self-efficacy. Yet, little is known about how family interventions may improve sleep behaviors and mental health in this vulnerable population.

The investigators previously completed RCT examined a home based, modified Cognitive Behavioral Therapy for Insomnia (CBT-I) intervention for children with ASD and insomnia (3, 4). The modified CBT-I is an 8 week intervention developed by the Principal Investigator that includes 1) A one hour education session developed by the Autism Treatment Network, Sleep Tool Kit (Appendix A); 2) Identifying positive evening routines, developing a visual schedule and implementing ecological changes to the bedroom, 3) Introducing a calming module with a choice of 5-12 soothing activities selected by the caregiver/child (Appendix B); and 3) Developing a bedtime protocol pairing irresistible sleepiness with the bedroom (stimulus control). The investigators study, using actigraphy an objective measure of sleep, showed that tailored CBT-I (n=20) decreased wake time in bed by 65 minutes with an effect size=1.05 compared to 19 minutes with an effect size=0.26 in the sleep education only group (n=16). The investigators study suggested that the tailored CBT-I has a larger effect than sleep education on sleep in children with ASD. However, this intervention required frequent and costly home visits by a multi-disciplinary team. In addition, 40% of mothers expressed that they had difficulty implementing CBT-I for their children due to exhaustion and feelings of being overwhelmed related to their own mental health.

To address this gap, the investigators propose to compare a home-based tailored CBT-I intervention versus a web-based Way to Health (WTH) platform tailored CBT-I intervention for caregivers with insomnia in the context of caring for a child with ASD and insomnia. This pilot RCT will further previous work and investigate the feasibility, acceptability, and efficacy of a web based versus home-based CBT-I intervention for both the caregiver with insomnia and the child with ASD and insomnia. The investigators also hope to gain a greater understanding of the relationships between child and caregiver sleep, caregiver psychiatric conditions, child behavior, and maternal self-efficacy. These findings will provide preliminary data for a larger RCT to improve sleep for all family members.

02

Conditions studied

  • Autism Spectrum Disorder
  • Insomnia Chronic
  • Caregiver Burden
03

In context

Autism Spectrum Disorder

1,727 studies on the registry are indexed under Autism Spectrum Disorder; 504 are open to participants now.

This study's planned enrollment of 80 is above the median of 52 across 1,371 interventional studies indexed under Autism Spectrum Disorder.

Browse Autism Spectrum Disorder studies →

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,635 studies on the registry; 239 are open to participants now.

Of its 154 completed or terminated interventional studies of FDA-regulated products, 104 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Caregiver with a child with ASD:

  • Caregiver age 18 years or older
  • Diagnosis of Insomnia
  • Parental/guardian will give permission (informed consent) for child
  • Telephone and web Access
  • Stable medical and behavioral conditions, with no change in health status in the past three months
  • Commitment to maintaining stable medication doses and keeping medication consistent

Inclusion Criteria for Children with ASD:

  • Children age 3 to 17 years and one of their parents
  • Diagnosis of Autism Spectrum Disorders, confirmed with Autism Diagnostic Observation Schedule and/or DSM-IV criteria.
  • Diagnosis of Behavioral Insomnia or Insomnia due to ASD (Insomnia due to internal
  • Parental/guardian permission (informed consent) and if appropriate, child assent.
  • Telephone and web Access
  • Stable medical and behavioral conditions, with no change in health status in the past
  • Commitment to maintaining stable medication doses and keeping child's sleep medication consistent

Key exclusion criteria for Caregiver and child with ASD:

  • Insomnia due to co-occurring medical conditions and/ or sleep disorders such as obstructive sleep apnea (OSA), narcolepsy, restless leg syndrome, severe reflux, nocturnal asthma
  • Unstable co-occurring medical conditions such as epilepsy or other neurological disorders, sickle cell anemia, diabetes or severe eczema
  • Significant hearing or vision loss
  • Known genetic disorders such as Fragile X, 22ql 1.2 Deletion Syndrome, Rett Disorder, Down Syndrome.
  • Subjects who, in the opinion of the Investigator, may be non¬ compliant with study schedules or procedures.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Home-based

    home- based CBT-Insomnia intervention

    Behavioral: Cognitive behavioral therapy for Insomnia

  • Experimental
    web-based

    web-based CBT-Insomnia intervention

    Behavioral: Cognitive behavioral therapy for Insomnia

Interventions

  • BehavioralCognitive behavioral therapy for Insomnia

    Caregiver with insomnia will receive CBT-Insomnia and will be trained to implement CBT-I tailored for their child with Autism Spectrum Disorder and Insomnia

06

What researchers measure

Primary outcomes

  1. Caregiver Acceptability Opinion Survey

    Opinion Survey with 8 items rated on a 7- point Likert scale. minimum of 0 and max of 56 with a score of 40 or greater will be considered acceptable for this study.

    Time frame: At week 8

  2. Feasibility of pilot study

    This study will be considered feasible if we obtain a 70% completion rate for the all measures.

    Time frame: At week 8

Secondary outcomes

  1. Change in reported sleep on sleep diaries

    Participants will be asked to record the amount of sleep each night

    Time frame: 8 weeks

  2. Change in Caregiver behaviors

    Depression questionnaire: Patient Health Questionnaire -9 with a minimum score of 0 and max of 27 with lower scores representing better outcome

    Time frame: week 8

  3. Change in Child Daytime behaviors

    Child Behavior Checklist (CBCL) T scores of 0 to 100 with lower scores representing better outcome

    Time frame: week 8

  4. Change in total sleep time average measured by an actigraphy watch for caregiver

    Total sleep time in minutes on average for the week

    Time frame: week 8

  5. Change in sleep latency as measured by actigraphy watch for caregiver

    sleep latency in minutes on average for the week

    Time frame: week 8

  6. Change in wake after sleep onset as measured by by actigraphy watch for caregiver

    wake after sleep onset in minutes on average for the week

    Time frame: week 8

  7. Change in total sleep time as measured by actigraphy watch for child

    Total sleep time in minutes on average for the week

    Time frame: week 8

  8. Change in sleep latency as measured by actigraphy watch for child

    sleep latency in minutes on average for the week

    Time frame: week 8

  9. Change in wake after sleep onset as measured by actigraphy for child

    wake after sleep onset in minutes on average for the week

    Time frame: week 8

  10. Change in Maternal Self-efficacy

    Maternal-Self efficacy Scale, 10 items with minimum score of 10 and maximum of 40 with higher scores representing better outcome

    Time frame: week 8

07

Study locations

2 sites
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19041, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: Yes — IPD sharing of all underlie results in publications

Supporting information: Study protocol, Sap, Icf, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05373537
Lead sponsor
University of Pennsylvania
Collaborators
Children's Hospital of Philadelphia
Responsible party
Sponsor
First posted
May 13, 2022
Start date
Nov 5, 2022
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Apr 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion